Literature DB >> 24904758

Molecular patterns of multidrug resistance of Mycobacterium tuberculosis in Georgia.

N Shubladze1, N Tadumadze1, N Bablishvili1.   

Abstract

BACKGROUND: Tuberculosis (TB) infections caused by multidrug-resistant Mycobacterium tuberculosis (MDR MTB) remain a significant public health concern worldwide. Georgia has a high prevalence of MDR MTB. The genetic mechanisms underlying the emergence of MDR MTB strains in this region are poorly understood and need to be determined for developing better strategies for TB control. This study investigated the frequency of major drug resistance mutations across rpoB, katG and inhA loci of Georgian MDR MTB strains and explored differences between new and previously treated patients. A total of 634 MTB strains were examined for which an MDR phenotype had been previously determined by the proportions method. The GenoType®MTBDRplus system was applied to screen the strains for the presence of rpoB (S531L, H526D, H526Y, and D516V), katG (S315T) and inhA promoter region (C15T and T8C) mutations. The target loci were amplified by PCR and then hybridized with the respective site-specific and wild type (control) probes.
RESULTS: Out of the 634 isolates tested considered by phenotypic testing to be resistant to RIF and INH, this resistance was confirmed by the GenoType®MTBDRplus assay in 575 (90.7%) isolates. RIF resistance was seen in 589 (92.9%) and INH resistance was seen in 584 (92.1%); 67.2% and 84.3% of MDR strains harbored respectively rpoB S531L and katG S315T mutations (generally known as having low or no fitness cost in MTB). The inhA C15T mutation was detected in 22.6% of the strains, whereas rpoB H526D, rpoB H526Y, rpoB D516V and inhA T8C were revealed at a markedly lower frequency (≤5.2%). The specific mutations responsible for the RIF resistance of 110 isolates (17.4%) could not be detected as no corresponding mutant probe was indicated in the assay. There was no specific association of the presence of mutations with the gender/age groups. All types of prevailing mutations had higher levels in new cases. A great majority of the Georgian MDR MTB strains have a strong preference for the drug resistance mutations carrying no or low fitness cost. Thus, it can be suggested that MDR MTB strains with such mutations will continue to arise in Georgia at a high frequency even in the absence of antibiotic pressure.

Entities:  

Keywords:  Fitness cost; GenoType®MTBDRplus; M. tuberculosis; Multidrug resistant tuberculosis; Mutation

Year:  2013        PMID: 24904758      PMCID: PMC4042859          DOI: 10.1016/j.ijmyco.2013.02.002

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  27 in total

Review 1.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

Review 2.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis.

Authors:  Leen Rigouts; Oscar Nolasco; Pim de Rijk; Elie Nduwamahoro; Armand Van Deun; Andy Ramsay; Jorge Arevalo; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

5.  Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays.

Authors:  T R Gingeras; G Ghandour; E Wang; A Berno; P M Small; F Drobniewski; D Alland; E Desmond; M Holodniy; J Drenkow
Journal:  Genome Res       Date:  1998-05       Impact factor: 9.043

6.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

7.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

8.  Reduced affinity for Isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance.

Authors:  Shengwei Yu; Stefania Girotto; Chiuhong Lee; Richard S Magliozzo
Journal:  J Biol Chem       Date:  2003-02-13       Impact factor: 5.157

9.  Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands.

Authors:  D van Soolingen; P E de Haas; H R van Doorn; E Kuijper; H Rinder; M W Borgdorff
Journal:  J Infect Dis       Date:  2000-10-26       Impact factor: 5.226

10.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.

Authors:  V I Enne; D M Livermore; P Stephens; L M Hall
Journal:  Lancet       Date:  2001-04-28       Impact factor: 79.321

View more
  6 in total

1.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

Review 2.  Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger
Journal:  Eur Respir J       Date:  2017-01-18       Impact factor: 16.671

3.  Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda.

Authors:  Edgar Kigozi; George W Kasule; Kenneth Musisi; Deus Lukoye; Samuel Kyobe; Fred Ashaba Katabazi; Eddie M Wampande; Moses L Joloba; David Patrick Kateete
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

4.  Evaluation of Genotype MTBDRplus and MTBDRsl Assays for Rapid Detection of Drug Resistance in Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in Pakistan.

Authors:  Hasnain Javed; Zofia Bakuła; Małgorzata Pleń; Hafiza Jawairia Hashmi; Zarfishan Tahir; Nazia Jamil; Tomasz Jagielski
Journal:  Front Microbiol       Date:  2018-09-26       Impact factor: 5.640

5.  Optimizing multiplex SNP-based data analysis for genotyping of Mycobacterium tuberculosis isolates.

Authors:  Sarah Sengstake; Nino Bablishvili; Anja Schuitema; Nino Bzekalava; Edgar Abadia; Jessica de Beer; Nona Tadumadze; Maka Akhalaia; Kiki Tuin; Nestani Tukvadze; Rusudan Aspindzelashvili; Elizabeta Bachiyska; Stefan Panaiotov; Christophe Sola; Dick van Soolingen; Paul Klatser; Richard Anthony; Indra Bergval
Journal:  BMC Genomics       Date:  2014-07-07       Impact factor: 3.969

6.  Establishment and evaluation of an overlap extension polymerase chain reaction technique for rapid and efficient detection of drug-resistance in Mycobacterium tuberculosis.

Authors:  Jungang Li; Jing Ouyang; Jing Yuan; Tongxin Li; Ming Luo; Jing Wang; Yaokai Chen
Journal:  Infect Dis Poverty       Date:  2022-03-24       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.